Association Between Hepatocellular Carcinoma and Diabetes Mellitus
Md Samiul Bashir1*, Moazzam Hossian2, Md. Khaja Mohi Uddin3, Md, Abu Sayem4, Afrin Sultana5, Faisal Akter Rana6, Tanzila Akter7, Nishita Das8, Md Sohel Rana9, Shib Shankar Das10
Journal of Primeasia 6(1) 1-7 https://doi.org/10.25163/primeasia.6110193
Submitted: 02 January 2025 Revised: 07 March 2025 Published: 15 March 2025
Abstract
Background: Diabetes Mellitus (T2DM) Type 2, presents a risk factor for the development of several chronic diseases, including Diabetes Mellitus Hepatocellular Carcinoma and Diabetes (HCC). Diabetes associated hyperglycemia is gaining importance due to the high prevalence of nonalcoholic fatty liver disease (NAFLD) which is a primary cause of liver fibrosis, cirrhosis, and HCC. This study is designed to evaluate the effect of T2DM on the progression of HCC along with its related metabolic markers in a Bangladeshi population. Methods: A laboratory based cross-sectional study was done at the Institute of Health Technology Laboratory, Kurigram, Bangladesh between June 2023 to May 2024. A total of 105 histologically confirmed HCC patients were included in the study through purposive sampling. Fasting blood sugar (FBS), 2 Hour Post Prandial glucose test (2HP), glycosylated Hemoglobin (HbA1c) and Alpha Feto-protein (AFP) blood biochemistry analyses were done. Data were analyzed using SPSS 26.0 software. Statistical significance was set at 5% level. Results: Participants had a mean age of 50.2 (SD=12.5). In the cohort, the majority (52%) were diabetic, others comprised 30% Prediabetic and 18% normal glycemic levels. All diabetic groups demonstrated elevated AFP levels along with total liver cirrhosis, while males had elevated levels compared to females(p=0.038). Conclusion: Diabetes-induced metabolic disorders are connected with liver injury due to the positive correlation between AFP level glycemic markers. The connection between diabetes and hepatocellular carcinoma is reinforced by raised AFP in diabetic patients. More research needs to be done to lessen the risk of HCC related to diabetes.Keywords: Hepatocellular Carcinoma (HCC), Diabetes Mellitus (DM), Alpha-Fetoprotein (AFP), Metabolic Dysfunction, Liver Disease.
References
Akter, T., Ali, M. R., Faruquee, M. N. A., Bashir, M. S., Rahaman, S., Rahman, M. A., & Islam, S. (2024). A comprehensive study of hepatitis B infections in Bangladesh: Epidemiology, risk factors, and clinical-laboratory correlations. Viral Infections and Cancer Research, 1(1), 8426. https://doi.org/10.59429/vicr.v1i1.8426
Bashir, S., Rana, S., Das, S. S., Sikder, N. F., Hossian, S., et al. (2024). Risk factors of cardiovascular disease among diabetic patients. Journal of Clinical and Laboratory Research, 7(8). https://doi.org/10.31579/2768-0487/151
Bazarbekova, R., Bektayeva, I., Konyrbayeva, A., Omarova, M., Abseitova, D., Kazbekova, A., Suslova, I., Moldasheva, A., Balazhanova, N., &Abdazimova, S. (2018). Hypoglycemic therapy and the risks of developing oncopathology among patients with type 2 diabetes (literature review). Journal Medicine, 198(12), 41–54. https://doi.org/10.31082/1728-452x-2018-198-12-41-54
Beasley, P. R. (2006). Diabetes and hepatocellular carcinoma. Hepatology, 44(6), 1408–1410. https://doi.org/10.1002/hep.21430
Chen, J., Han, Y., Xu, C., & Wang, T. X. a. B. (2015). Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases. European Journal of Cancer Prevention, 24(2), 89–99. https://www.jstor.org/stable/48504426
Chen, J., Han, Y., Xu, C., Xiao, T., & Wang, B. (2014). Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases. European Journal of Cancer Prevention, 24(2), 89–99. https://doi.org/10.1097/cej.0000000000000038
Das, B. K., & Gadad, P. C. (2021). Impact of diabetes on the increased risk of hepatic cancer: An updated review of biological aspects. Diabetes Epidemiology and Management, 4, 100025. https://doi.org/10.1016/j.deman.2021.100025
Di Bisceglie, A. M., Carithers, R. L., & Gores, G. J. (1998). Hepatocellular carcinoma. Hepatology, 28(4), 1161–1165. https://doi.org/10.1002/hep.510280436
Doycheva, I., Zhang, T., Amjad, W., &Thuluvath, P. J. (2019). Diabetes and Hepatocellular Carcinoma: Incidence trends and impact of liver disease etiology. Journal of Clinical and Experimental Hepatology, 10(4), 296–303. https://doi.org/10.1016/j.jceh.2019.11.004
El-Serag, H. B., Tran, T., & Everhart, J. E. (2004). Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology, 126(2), 460–468. https://doi.org/10.1053/j.gastro.2003.10.065
Ghannei, O., Mssad, R., Amor, S. B., &Trimech, M. (2023). Impact du diabète sur la survenue de carcinomehépatocellulaire chez les patients cirrhotiques. Annales D Endocrinologie, 84(5), 649. https://doi.org/10.1016/j.ando.2023.07.406
Hassan, M. M., Hwang, L., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., Beasley, P., &Patt, Y. Z. (2002). Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36(5), 1206–1213. https://doi.org/10.1053/jhep.2002.36780
International, 2017, 1–10. https://doi.org/10.1155/2017/5202684
Johnston, M. P., Patel, J., & Byrne, C. D. (2020). Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy. HepatoBiliary Surgery and Nutrition, 9(2), 230–234. https://doi.org/10.21037/hbsn.2019.10.09
Komura, T., Mizukoshi, E., Kita, Y., Sakurai, M., Takata, Y., Arai, K., Yamashita, T., Ohta, T., Shimizu, K., Nakamoto, Y., Honda, M., Takamura, T., & Kaneko, S. (2007). Impact of Diabetes on Recurrence of Hepatocellular Carcinoma after Surgical Treatment in Patients with Viral Hepatitis. The American Journal of Gastroenterology, 102(9), 1939–1946. https://doi.org/10.1111/j.1572-0241.2007.01354.x
Li, X., Wang, X., & Gao, P. (2017). Diabetes mellitus and risk of hepatocellular carcinoma. BioMed Research International, 2017, 1–10. https://doi.org/10.1155/2017/5202684
Li, X., Wang, X., & Gao, P. (2017b). Diabetes mellitus and risk of hepatocellular carcinoma. BioMed Research
Matteoni, C., Younossi, Z., Gramlich, T., Boparai, N., Liu, Y., &Mccullough, A. (1999). Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity?, ??. Gastroenterology, 116(6), 1413–1419. https://doi.org/10.1016/s0016-5085(99)70506-8
Putra, N. M. I. W. T., &Harahap, N. a. D. N. (2024). The Analysis Study of Association of Type 2 Diabetes mellitus and Hepatocellular Carcinoma?: A Comprehensive Systematic Review. The Indonesian Journal of General Medicine, 7(4), 67–85. https://doi.org/10.70070/x66ng691
Rana, M. S., Bashir, M. S., Das, S. S., Hossain, M., &Barua, S. (2024).Biomarkers forhepatocellular carcinoma: Diagnosis, prognosis, and treatment response assessment – A systematic review. Journal of Primeasia, 5(1), 1–8. https://doi.org/10.25163/primeasia.519784
Rana, M. S., Uddin, N., Bashir, M. S., Das, S. S., Islam, M. S., &Sikder, N. F. (2023). Effect of Stereospermumpersonatum, Senna obtusifolia, and Amomumsubulatum extract in hypoglycemia on Swiss albino mice model. Pathfinder of Research, 1(1).
Ruhl, C. E., & Everhart, J. E. (2003). Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology, 124(1), 71–79. https://doi.org/10.1053/gast.2003.50004
Salam, M. T., Mou, M. A., et al. (2024). Assessment of lipid profile in hepatocellular carcinoma patients: A prospective study in Bangladesh. Journal of Primeasia, 5(1), 1–8. https://doi.org/10.25163/primeasia.519787
Talamantes, S., Lisjak, M., Gilglioni, E. H., Llamoza-Torres, C. J., Ramos-Molina, B., &Gurzov, E. N. (2023). Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma. JHEP Reports, 5(9), 100811. https://doi.org/10.1016/j.jhepr.2023.100811
Tolman, K. G., Fonseca, V., Tan, M. H., &Dalpiaz, A. (2004). Narrative Review: Hepatobiliary disease in Type 2 diabetes mellitus. Annals of Internal Medicine, 141(12), 946. https://doi.org/10.7326/0003-4819-141-12-200412210-00011
Tufael, A., Kar, A., Upadhye, V. J., Dutta, A., Islam, M. R., Sattar, A., Ali, M. E., Akter, J., Bari, K. F., Salam, M. T., Banik, P. C., Khan, M. S. S., & Sunny, A. R. (2024). Significanceof serum biomarkers in early diagnosis of hepatocellular carcinoma in patients with fisher groups. Journal of Angiotherapy, 8(1), 1–9. https://doi.org/10.25163/angiotherapy.819440
Tufael, AuditiKar et al., (2024). Diagnostic Efficacy of Tumor Markers AFP, CA19-9, and CEA in Hepatocellular Carcinoma Patients, Journal of Angiotherapy, 8(4), 1-10, 9513 https://doi.org/10.25163/angiotherapy.849513
Tufael, MdMostafizur Rahman et al. (2024). Combined Biomarkers for Early Diagnosis of Hepatocellular Carcinoma, Journal of Angiotherapy, 8(5), 1-12, 9665 https://doi.org/10.25163/angiotherapy.859665
Venugopal, S., Dhanoa, R. K., Selvamani, T. Y., Shoukrie, S. I., Zahra, A., Malla, J., Selvaraj, R., Hamouda, R. K., & Mohammed, L. (2023). Does type 2 diabetes increase the risk of hepatocellular carcinoma in nonalcoholic fatty liver disease patients: a systematic review. Cureus. https://doi.org/10.7759/cureus.36079
Wainwright, P., Scorletti, E., & Byrne, C. D. (2017). Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis. Current Diabetes Reports, 17(4). https://doi.org/10.1007/s11892-017-0851-x
Zen, Y., Katayanagi, K., Tsuneyama, K., Harada, K., Araki, I., &Nakanuma, Y. (2001). Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathology International, 51(2), 127–131. https://doi.org/10.1046/j.1440-1827.2001.01174.x
View Dimensions
View Altmetric
Save
Citation
View
Share